Perspective Therapeutics (CATX) Equity Ratio (2011 - 2026)

Perspective Therapeutics has disclosed Equity Ratio across 16 years of filings, most recently posting 0.85 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.85, down 2.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.85 (down 2.13% YoY), and the FY2025 annual result was 0.78, down 9.0% from the prior year.
• Equity Ratio came in at 0.85 for Q1 2026 at Perspective Therapeutics, up from 0.78 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.96 in Q1 2022 to a low of 0.77 in Q4 2023.
• The 5-year median for Equity Ratio is 0.86 (2025), against an average of 0.87.
• Across the five-year window, Equity Ratio retreated 18.35% in 2023 and increased 10.96% in 2024, its largest moves.
• Perspective Therapeutics' Equity Ratio stood at 0.94 in 2022, then dropped by 18.35% to 0.77 in 2023, then grew by 10.96% to 0.85 in 2024, then dropped by 9.0% to 0.78 in 2025, then grew by 9.07% to 0.85 in 2026.
• The last three Equity Ratio figures came in at 0.85 (Q1 2026), 0.78 (Q4 2025), and 0.82 (Q3 2025), per Business Quant data.